PMA supplement
P250009 S002: SQUID Liquid Embolic Agent (LEA)
FDA PMA supplement · Real-Time Process · Balt USA, LLC
Key facts
| Original PMA | P250009 |
|---|---|
| Supplement number | S002 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | SQUID Liquid Embolic Agent (LEA) |
| Generic name | Neurovascular Liquid Embolic Agent |
| Applicant | Balt USA, LLC |
| Product code | SGU |
| Received date | Jun 15, 2026 |
| Decision date | Sep 9, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: